<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024530</url>
  </required_header>
  <id_info>
    <org_study_id>IVY02</org_study_id>
    <nct_id>NCT01024530</nct_id>
  </id_info>
  <brief_title>Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Kong Wu Ho-Su Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ivy Life Sciences, Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shin Kong Wu Ho-Su Memorial Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune
      killer cells in treating hepatocellular carcinoma patients in：

        1. Reduction of tumor size

        2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome Measure: Reduction of tumor size</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.All cause survival rate 2.The relapse rate: frequency of TACE treatment 3.Reduction of AFP value 4.Improvement of VAS scale and QOL（Quality of life）</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Biological treament</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous immune killer cells plus TACE(Transcatheter Arterial Chemoembolization)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE (Transcatheter Arterial Chemoembolization)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>immune killer cells (IKC)</intervention_name>
    <description>autologous immune killer cells</description>
    <arm_group_label>Biological treament</arm_group_label>
    <arm_group_label>TACE (Transcatheter Arterial Chemoembolization)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign and give written informed consent.

          2. Age≧20 years, but＜80 years.

          3. Hepatocellular carcinoma by CT, MRI, AFP, angiography or cytology/biopsy examinations.

          4. Barcelona staging system stage B and C.

          5. Never receive TACE treatment and comply with the standard of TACE treatment.

          6. Child-Pugh stage A and B.

          7. ECOG performance status 0 to 2.

        Exclusion Criteria:

          1. Participant of other clinical trial within the past 4 weeks of screening period.

          2. Receiver of chemotherapy, radiotherapy, immunotherapy, hormone therapy, local tumor
             therapy, or target therapy within the past 4 weeks of screening period.

          3. Carriers of HIV or HTLV within the past 4 weeks of screening period.

          4. With Active acute or chronic infection（by investigator's judgement）.

          5. Other diseases, except hepatocellular carcinoma, which are life-threatening to the
             patients（by investigator's judgement)for example:

             5.1 Active cardiac disease requiring therapy for coronary artery disease, congestive
             heart failure, arrhythmia or myocardial infarction.

             5.2 With previous history of encephalopathy within the past six months. 5.3 Involved
             Involving systemically or known central nerve system diseases（brain or meningeal
             metastasis）.

          6. Women of pregnant or breast-feeding or child-bearing potential but without adequate
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Jiun Chen</last_name>
      <phone>886966149672</phone>
    </contact>
    <investigator>
      <last_name>Kuo Ching Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>December 11, 2009</last_update_submitted>
  <last_update_submitted_qc>December 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Wang Tien-Chin</name_title>
    <organization>IVY LIFE SCIENCES CO.,LTD</organization>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>NK</keyword>
  <keyword>immune killer cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

